Equillium Inc

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.

Complete response observed in five of seven patients in first two dose cohorts

Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study

LA JOLLA, Calif., July  30, 2020  (GLOBE NEWSWIRE) --  Equillium, Inc.  (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., Equillium’s chief medical officer, will participate in a fireside discussion at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020.

Equillium to Present at BTIG Virtual Biotechnology Conference 2020

Equillium (EQ) news for Tuesday concerning a deal with Jefferies (JEF) to sell shares of EQ stock has it falling on Tuesday.
The post Equillium News: Why EQ Stock Is Plummeting 46% Today appeared first on InvestorPlace.

Equillium News: Why EQ Stock Is Plummeting 46% Today

Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.

Equillium Gains From Positive Results on Coronavirus Drug

Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon

Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19

LA JOLLA, Calif., May  13, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2020.

Equillium Reports First Quarter 2020 Financial Results

LA JOLLA, Calif., March  30, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. 

Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic

Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

Maple Fung, M.D., joins as vice president clinical development  Matthew Ritter, Ph.D., joins as vice president corporate development

Equillium Strengthens Leadership Team with Key Appointments

As of late, it has definitely been a great time to be an investor in Equillium.

Will Equillium Continue to Surge Higher?

Equillium has been struggling lately, but the selling pressure may be coming to an end soon.

Equillium Sees Hammer Chart Pattern: Time to Buy?

As of late, it has definitely been a great time to be an investor Equillium

Can The Uptrend Continue for Equillium?

LA JOLLA, Calif. and BENGALURU, India, Dec.  12, 2019  (GLOBE NEWSWIRE) --  Equillium Inc.  (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, and Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

LA JOLLA, Calif., Dec.  09, 2019  (GLOBE NEWSWIRE) --  Equillium, Inc.  (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for itolizumab for the treatment of lupus nephritis. Equillium initiated the  EQUALISE Phase 1b study  of itolizumab in patients with lupus and lupus nephritis in September 2019.

Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis

As of late, it has definitely been a great time to be an investor Equillium.

Equillium Shares March Higher, Can It Continue?

LA JOLLA, Calif., Nov.  15, 2019  (GLOBE NEWSWIRE) --  Equillium, Inc.  (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Krishna R. Polu, M.D., chief medical officer, will participate in a panel discussing “New Innovations in Drug Therapy” as part of the Kidney Capital Markets Day hosted by the American Society of Nephrology (ASN) and RenalytixAI on Tuesday, November 19, 2019 in London, England.

Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health

Effective January 1, 2020 Bruce Steel will assume role of Chief Executive Officer, and  Dan Bradbury will remain on the Board of Directors as Executive Chairman

Equillium Announces Leadership Updates

Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC

Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update

LA JOLLA, Calif., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders will be hosting a call with shareholders and the investment community to provide a business update on Tuesday, October 1, 2019.  Dan Bradbury, Equillium’s chairman and chief executive officer, and other members of Equillium’s management team will participate in the call. During the call the Company plans to provide an update on its clinical development programs and corporate milestones.

Equillium to Host Business Update Call on October 1, 2019

LA JOLLA, Calif., Aug.  27, 2019  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s president and chief business officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019. 

News for Equillium Inc Stock (EQ)